Acquired resistance mechanisms to osimertinib: the constant battle

Lung cancer is the leading cause of cancer-related mortality worldwide, mainly due to poor overall survival and late-stage initial diagnosis [1]. Non-small-cell lung cancer (NSCLC) represents nearly 85% of lung cancers [2]. Recently, detectable driver mutations have revolutionized lung cancer treatment with the emergence of targeted therapy as a novel therapeutic strategy that has widely improved lung cancer prognosis, especially in metastatic patients [2]. Adenocarcinoma, the most common subtype of NSCLC, is where most mutations occur.

Source: Cancer Treatment Reviews - April 6, 2023 Category: Cancer & Oncology Authors: Ziad Zalaquett, Maria Catherine Rita Hachem, Yara Kassis, Samir Hachem, Roland Eid, Hampig Raphael Kourie, David Planchard Tags: Anti-tumour Treatment Source Type: research